However, this approach may be less effective in many CML patients, who develop resistance despite the effective inhibition of BCR::ABL1 with TKIs, i.e., with BCR::ABL1-independent resistance mechanisms. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.